CEFALY Technology Launches Groundbreaking Registry for Migraine Treatment in Expecting Mothers

CEFALY Technology Launches New Pregnancy Registry for Migraine Treatment

In an important step towards enhancing migraine care, CEFALY Technology has launched the CEFALY Pregnancy Registry, an initiative aimed at collecting crucial data on the safety of external trigeminal nerve stimulation (eTNS) as a potential treatment for migraines during pregnancy. This innovative registry comes at a time when safe treatment options for migraines in expectant mothers are limited.

Understanding the Importance of Research

Migraine is a prevalent and debilitating condition that affects millions globally, with an estimated 39 million Americans suffering from it. It is particularly common among women of childbearing age, with approximately 75% of migraine sufferers being female. During pregnancy, managing migraine can pose numerous challenges. Many expectant mothers find themselves with few pharmacological options, as numerous medications may pose risks to their unborn children. Thus, non-pharmacological treatments such as eTNS have gained traction.

The newly established CEFALY Pregnancy Registry aims to fill the research gap surrounding the use of eTNS during pregnancy. The registry is actively seeking women aged 18 to 44 who are currently pregnant with a single baby and have previously experienced headaches or migraines, as well as those who developed these conditions during their pregnancy.

Participation and Data Collection

Participants will engage in a series of online surveys throughout and post-pregnancy. It is important to note that registry participation does not require the use of the CEFALY device or any external nerve stimulators. Those who complete the registry will receive compensation, making it a valuable opportunity for women willing to contribute to this important research.

Data collection and management for the CEFALY Pregnancy Registry will be conducted by Greenlight Guru Clinical, a recognized leader in clinical trial data collection for medical devices. This collaboration aims to ensure that the data collected is both reliable and relevant to the challenges faced by pregnant women with migraine.

An Urgent Need for Safe Treatments

Jen Trainor McDermott, CEO of CEFALY Technology, emphasized the urgent need for research in this area. "For far too long, women have struggled to find a safe and effective treatment option for migraines during pregnancy. Many believe they must suffer in silence. We hope to make life better for millions of moms-to-be by studying the safety of eTNS migraine therapy during pregnancy," she stated.

This initiative indicates a shift towards prioritizing women's health in research, particularly for conditions that disproportionately affect them. The registry not only promises to generate essential safety data but also aims to empower women by providing them with better management options.

About the CEFALY Device

CEFALY Technology is renowned for its flagship product, the CEFALY device – an FDA-cleared, over-the-counter wearable medical device designed to help reduce the frequency and severity of migraines. The CEFALY device applies stimulation to the trigeminal nerve, a pivotal area involved in pain perception related to migraines. The device is designed to be user-friendly and effective, providing an essential tool for migraine management.

In addition to the device, the CEFALY Connected offers Bluetooth functionality, syncing with the CeCe Migraine Management app. This app helps users track their treatment and migraine occurrences, providing insight into their migraine patterns and treatment effectiveness.

Company Background

Based in Belgium, with operations in Darien, Connecticut, CEFALY Technology focuses on electronics for medical applications. Their mission revolves around developing innovative and evolving solutions that enable migraine sufferers to regain control over their treatment.

For more information on participating in the CEFALY Pregnancy Registry, interested individuals can visit the dedicated registry page at CEFALY Pregnancy Registry. This initiative could bring transformative changes to the way migraines are understood and treated during pregnancy, ultimately improving the quality of life for many women.

With ongoing challenges in migraine management, CEFALY and the new registry represent hope for better solutions tailored to meet the unique needs of pregnant women suffering from this condition.